Bionano Genomics (BNGO) Projected to Post Quarterly Earnings on Monday

Bionano Genomics (NASDAQ:BNGO) is anticipated to post its Q4 2025 results after the market closes on Monday, March 23rd. Analysts expect Bionano Genomics to post earnings of ($0.81) per share and revenue of $7.88 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 23, 2026 at 4:30 PM ET.

Bionano Genomics Stock Performance

Bionano Genomics stock opened at $1.11 on Monday. Bionano Genomics has a fifty-two week low of $1.06 and a fifty-two week high of $5.50. The stock’s 50 day simple moving average is $1.30 and its two-hundred day simple moving average is $1.78. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.82 and a current ratio of 2.12. The stock has a market cap of $11.30 million, a price-to-earnings ratio of -0.23 and a beta of 1.68.

Hedge Funds Weigh In On Bionano Genomics

A number of institutional investors and hedge funds have recently made changes to their positions in BNGO. DRW Securities LLC purchased a new position in shares of Bionano Genomics during the fourth quarter valued at approximately $258,000. Geode Capital Management LLC grew its stake in shares of Bionano Genomics by 148.8% in the 4th quarter. Geode Capital Management LLC now owns 66,766 shares of the company’s stock worth $102,000 after buying an additional 39,928 shares during the last quarter. Carret Asset Management LLC increased its position in Bionano Genomics by 76.4% during the 4th quarter. Carret Asset Management LLC now owns 44,100 shares of the company’s stock valued at $67,000 after buying an additional 19,100 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Bionano Genomics during the fourth quarter valued at $57,000. Finally, Jane Street Group LLC purchased a new position in Bionano Genomics during the fourth quarter valued at $34,000. Institutional investors own 11.35% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on BNGO shares. HC Wainwright restated a “buy” rating and issued a $7.00 target price (down from $11.00) on shares of Bionano Genomics in a research note on Monday, November 24th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bionano Genomics in a research note on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Bionano Genomics presently has a consensus rating of “Hold” and a consensus price target of $5.50.

About Bionano Genomics

Bionano Genomics, Inc (NASDAQ: BNGO) develops and commercializes high‐resolution genome analysis tools designed to map structural variants and large‐scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase‐length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity.